Company news
Kura Oncology, Inc. news in 2019
Kura Oncology, Inc.'s news releases, calls and decks from 2019, newest first.
Kura Oncology Receives Fast Track Designation for Tipifarnib in HRAS Mutant HNSCC and Provides Enrollment Guidance for AIM-HN Trial
December 15, 2019
Kura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma
December 7, 2019
Kura Oncology Announces Upcoming Presentation at ASH Annual Meeting
November 5, 2019
Kura Oncology Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 4, 2019
Kura Oncology Appoints James Basta as Chief Legal Officer
November 3, 2019
Kura Oncology Reports Durable Anti-Tumor Activity in Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer
October 28, 2019
Kura Oncology Announces Upcoming Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 15, 2019
Kura Oncology Expands Board of Directors with Appointment of Diane Parks
October 14, 2019
Kura Oncology Doses First Patient in Phase 1 Clinical Trial of Menin-MLL Inhibitor KO-539 in Acute Myeloid Leukemia
September 15, 2019
Decks in 2019
- Technical Presentation (December 2019)
Technical · 21 slides · Dec 8, 2019
- Technical Presentation (June 2019)
Technical · 21 slides · Jun 14, 2019
- Investor Presentation (January 2019)
Investor deck · 40 slides · Jan 7, 2019
- 24th Congress of the European Hematology Association (EHA) 2019
Conference · 17 slides · 2019
- Technical Presentation (2019)
Technical · 18 slides · 2019
- AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019
Conference · 10 slides · 2019